Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the ...

has held his now-atrophied arm aloft for more than half a century. The congregation disperses at dawn as pilgrims fan out into the river for their sun salutations. A bearded sadhu from Kashmir ...

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...

In 2023, the FDA approved two drug treatments for geographic atrophy in dry AMD ... of 5.4 letters in the treatment arm and three letters in the sham arm, which, Sadda stated, raises the ...

There were approximately 20 patients per arm in the mITT ... as assessed by the MSA atrophy index (MSA-AI)3 NfL: The analysis of neurofilament light chain (NfL) levels in spinal fluid is ongoing ...

There were approximately 20 patients per arm in the mITT. Both clinical doses demonstrated ... to placebo at both 50 mg and 75 mg dose levels, as assessed by the MSA atrophy index (MSA-AI) 3 NfL: The ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal stimulation.

His disability means he has significantly reduced mobility in his right arm and leg, with many muscles now atrophied as a result. “I am on the ground floor but I can't use the shower.